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Summary
 
Objective
 
Familial glucocorticoid deficiency (FGD) is a rare auto-
somal recessive disease characterized by isolated glucocorticoid
deficiency with preserved mineralocorticoid secretion. Mutations in
the ACTH receptor (MC2R) account for approximately 25% of
all FGD cases, but since these are usually missense mutations, a
degree of receptor function is frequently retained. A recent report,
however, suggested that disturbances in the renin–aldosterone axis
were seen in some patients with potentially more severe MC2R
mutations. Furthermore, MC2R knock out mice have overt
aldosterone deficiency and hyperkalaemia despite preservation of a
normal zona glomerulosa. We wished to determine whether a group
of patients with severe nonsense mutations of the MC2R exhibited
evidence of mineralocorticoid deficiency, thereby challenging the
conventional diagnostic feature of FGD which might result in
diagnostic misclassification.
 
Design
 
Clinical review of patients with nonsense MC2R mutations.
 
Patients
 
Between 1993 and 2008, 164 patients with FGD were
screened for mutations in the MC2R. Totally 42 patients (34 families)
were found to have mutations in the MC2R. Of these, 6 patients (4
families) were found to have homozygous nonsense or frameshift
mutations.
 
Results
 
Mild disturbances in the renin–angiotensin–aldosterone
axis were noted in four out of six patients, ranging from slightly
elevated plasma renin levels to low aldosterone levels, although frank
mineralocorticoid deficiency or electrolyte disturbance were not
found. No patient required fludrocortisone replacement.
 
Conclusion
 
Severe nonsense and frameshift MC2R mutations are
not associated with clinically significant mineralocorticoid deficiency and
are thus unlikely to require long-term mineralocorticoid replacement.
(Received 5 November 2008; returned for revision 24 November 
 
2008; finally revised 1 December 2008; accepted 2 December 2008)
 
Introduction
 
Familial glucocorticoid deficiency (FGD) (OMIM: #202200),
otherwise known as hereditary unresponsiveness to ACTH, is a rare
autosomal recessive disease characterized by isolated glucocorticoid
deficiency in the absence of mineralocorticoid deficiency. Patients
usually present in early childhood with symptoms associated with
cortisol deficiency including recurrent illnesses/infections,
hypoglycaemia, convulsions, failure to thrive and shock.
 
1
 
 Biochemical
assessment will typically reveal extremely high plasma ACTH levels
with associated low to undetectable serum cortisol and normal renin
and aldosterone levels.
 
1–5
 
Inactivating mutations in the ACTH receptor/MC2R in patients
with FGD were first described in 1993.
 
2,3
 
 Since then many other
mutations have been identified which account for approximately
25% of cases of FGD (reviewed in Ref. [1]). These mutations are
scattered throughout the receptor and the majority are homozygous
or compound heterozygous missense mutations leading to sub-
stitution of a single amino acid by another. 
 
In vitro
 
, missense
mutations have been shown to result in varying degrees of impaired
ACTH signalling, most often by affecting trafficking of the receptor
to the cell surface, but also by disruption of ligand binding and loss
of signal transduction.
 
4–7
 
 In comparison, homozygous nonsense and
frameshift mutations are extremely rare and only one such mutation
has been reported.
 
8
 
 The expected result of such mutations would be
a significantly truncated protein severely disrupting MC2R function.
 
9
 
Assessment of one truncating mutation of this type, the 652insA
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mutation (insertion of a single adenine resulting in a frameshift after
the glycine residue at amino acid position 217), revealed severely
impaired function of this mutant receptor.
 
6
 
 This raises the possibility
that nonsense or frameshift mutations of the MC2R may be
associated with a distinct clinical phenotype with the consequence that
these patients are not classified as having FGD on clinical criteria.
The classical phenotype of FGD is that of isolated glucocorticoid
deficiency. However, it has long been recognized that minor
impairment of the renin–angiotensin–aldosterone axis is seen in some
patients at the time of presentation.
 
10,11
 
 The significance of this
observation is unclear as the changes are usually transient and
mineralocorticoid treatment is not required. In normal human
physiology, aldosterone secretion is primarily determined by the
levels of angiotensin II. However, ACTH acting through the MC2R in the
zona glomerulosa (ZG) is an efficient stimulus to aldosterone secretion,
and administration of synthetic ACTH (1-24) to normal human subjects
results in a rise in plasma aldosterone levels.
 
11
 
 Failure of this path –
especially in times of stress – may impair aldosterone production.
Recently published data on the MC2R knockout (KO) mice
revealed that these mice have low serum aldosterone levels leading
to hyperkalaemia in females, and increased expression of the
angiotensin receptor 1b (AT1bR) in the ZG, implying an element of
compensation in the renin–angiotensin–aldosterone axis in the
complete absence of MC2R.
 
12,13
 
 Furthermore, Lin
 
 et al
 
. recently
described a series of children with MC2R mutations who had a
degree of increased renin activity or aldosterone deficiency at initial
investigation and were treated with 9
 
α
 
-fludrocortisone. Amongst
these was one child with a homozygous deletion in the MC2R leading
to a nonfunctional receptor and who had elevated plasma renin
activity (PRA), low aldosterone concentrations and electrolyte
disturbance.
 
8
 
These data suggest that human MC2R mutations which result in
the total absence of functional MC2R may result in disruption of
renin–angiotensin–aldosterone axis and potentially the categorization
of these patients as having adrenal hypoplasia rather than FGD.
In an attempt to examine this hypothesis we identified six previously
unreported patients (out of 164 FGD patients) with novel frameshift
and nonsense MC2R mutations, and retrospectively sought evidence
of mineralocorticoid deficiency.
 
Methods
 
Patients
 
A total of 164 FGD patients referred from national and international
centres from 1993 to 2008 were screened in our laboratory for
mutations in MC2R. All patients had elevated plasma ACTH and
low to undetectable serum cortisol levels. Forty-two individuals
from 34 families were found to have mutations in the MC2R
(25·6%). Half of these were homozygous S74I missense mutations
(21 patients from 16 families).
 
2
 
 Among the group of patients
screened, six patients from four families were identified with
homozygous nonsense or frameshift mutations. Clinical details and
their endocrine investigations are summarized in Table 1. In all cases,
informed consent for mutational analysis was obtained. The study
was approved by the local institutional ethic committee.
 
Biochemical investigations
 
Biochemical investigations were performed at the referring institute;
all cases were assessed by a paediatric endocrinologist at a tertiary
centre. Age appropriate, centre specific normal values were provided
by the lead clinicians and are shown in Table 1.
 
Mutational analysis of MC2R
 
Genomic DNA was extracted from blood leucocytes. PCR of the
single coding exon was performed using specific intronic primers
(primer sequences and PCR conditions available on request). PCR
products were visualized on a 1% agarose gel, and sequenced using
the ABI Prism Big Dye Sequencing kit and an ABI 3700 automated
DNA sequencer (Applied Biosystems) in accordance with the
manufacturer’s instructions. Mutations were confirmed on two
independent PCRs sequenced in both directions and described in
accordance to recommended nomenclature.
 
14
 
Results
 
Patient I:1 – 
 
c.
 
459_460insC resulting in p.I154fsX248
 
Patient I:1 presented with neonatal hepatitis and hypoglycaemia at
day 3 of life. He was the second child of a consanguineous Kuwaiti
family. His 8 years old brother was unaffected. He was treated for
presumed sepsis and investigated for his neonatal hepatitis. He
was found to have a high TSH and low FT
 
4
 
 and diagnosed with hypo-
thyroidism. Treatment was initiated with levothyroxine. There was a
family history of thyroid disorders, with Hashimoto thyroiditis
(father) and a paternal cousin with panhypopituitarism. He was
reassessed at the age of 7 months and diagnosed with glucocorticoid
deficiency and initiated on hydrocortisone treatment. Biochemical
assessment revealed an undetectable serum cortisol level of
< 30 nmol/l during a hypoglycaemic episode (blood glucose was
1·9 mmol/l). Plasma ACTH levels were elevated to 639 ng/l. Serum
sodium was 132 mmol/l with a normal potassium level of 4·5 mmol/l.
A short synacthen test showed no response to 1–24 ACTH, baseline
cortisol was 21 nmol/l and peak of 10 nmol/l. Hyperpigmentation
was noted and in hindsight parents had commented on his dark skin
soon after birth. Adrenal and thyroid antibodies were negative.
A diagnosis of FGD was considered at 5·9 years of age when he was
reassessed at a separate centre. While on hydrocortisone replacement,
plasma renin levels were deemed ‘very high’ during an admission
for a glucagon stimulation test. This was considered to be due to an
element of hypovolaemia during the test. Aldosterone levels were
normal at 100 pmol/l (N.R. 100–450 pmol/l). Subsequent repeat
renin levels performed while clinically well on treatment
showed a PRA on the upper range of normal (4·5 pmol/ml/h; N.R.
2·8–4·5 pmol/ml/h). Further assessment at 10·8 years, while on
hydrocortisone treatment the patient showed a persistently elevated
plasma ACTH level of 7790 ng/l (N.R. < 50 ng/l), typical of FGD.
Aldosterone level was low < 70 pmol/l, paired with a slightly high
PRA of 6·7 pmol/ml/h, suggestive of a degree of mineralocorticoid
deficiency. He remains well on hydrocortisone treatment
10·2 mg/m
 
2
 
/day. Mutational analysis of the MC2R revealed a
 M
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Table 1.
 
Clinical and biochemical data on all six patients with homozygous MC2R nonsense and frameshift mutations
Family I II III IV
Patient number 1 1 2 1 1 2
MC2R mutation c.459–460insC 
(p.I154fsX248)
c.634delA 
(p.R212fsX215)
c.634delA 
(p.R212fsX215)
c.702delC 
(p.F235fsX241)
c.539C > 
A (p.S180X)
c.539C > A 
(p.S180X)
Sex M F M M M F
Age of first S/D 3 days/7 months 10 days/1 month 16 months 7 weeks 2 days/4 weeks 6 days
Age at Last F 10·8 years 4·8 years 2·7 years 1 year 15 years 12 years
Presentation Neonatal hepatitis, 
hyperpigmentation, 
prolonged jaundice
Hypoglycaemic 
seizures, sepsis
Hypoglycaemic 
seizures
Hypoglycaemia, 
hyperpigmentation, 
prolonged jaundice, FTT
Hypoglycaemic 
seizures, 
hyperpigmentation
Hypoglycaemic seizures 
Hyperpigmentation,
Cortisol (nmol/l) D < 30 < 30 < 30 < 30 < 30 < 30
(N.R. 120–620)
ACTH (pg/ml) D 639 – > 1250 > 1250 > 3000 > 3000
(N.R. < 50) F 7790 < 5† < 6† NA NA –
Aldosterone (pmol/l) D 100‡ 470 320 NA NA 939
F
 
< 70
 
190 650
 
70/290
 
NA 103
N.R. 100–450 100–440 83–840 300–2200 NA 83–941
Plasma renin/plasma 
renin activity
D 4·5 pmol/ml/h‡
 
433 
 
 
μ
 
U/ml 63 
 
 
μ
 
U/ml
 
NA NA
 
> 19 pmol/ml/h
 
F
 
6·7 pmol/ml/h 68·7 
 
 
μ
 
U/ml 80·2 
 
 
μ
 
U/ml
 
3·5 pmol/ml/h, 
5·6 pmol/ml/h
 
0·6–9·1 pmol/ml/h
 
12·8 ng/l (7·4–56·2)§
N.R. 2·8–4·5 3·9–49·3 3·3–41 1·3–8·6 1·2–5·3 1·2–5·3
UE at D and F Na +132 at D, Normal at F Normal Normal Normal Normal Normal
Treatment (mg/m
 
2
 
/day) HC 10·2 HC 19·5 HC 23·4 HC 20 HC 12·9 HC 14·5
SI conversion: Aldosterone, pmol/l = 27·7 ng/dL, PRA, pmol/h/ml = 0·77 ng/h/ml, was used where appropriate. D, at diagnosis; HC, hydrocortisone; UE, urea and electrolytes; S, symptoms; FTT, failure to thrive; 
F, follow-up; NR, normal range; NA, results not available. †Suppression of ACTH on high doses of HC. ‡Results taken age 5·9 years (date of FGD diagnosis). Abnormal renin/aldosterone results in bold. 
§Corresponding NR in ng/l.
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homozygous insertion of a cytosine (C) at nucleotide positions
459–460. At a protein level this would result in a substitution of the
isoleucine residue at amino acid position 154 by a histidine and
subsequent frameshift leading to a nonsense sequence and premature
termination of the receptor at position 248 (p.I154fsX248).
Both parents were assessed and found to be heterozygous for the C
nucleotide insertion.
 
Patients II:1 and II:2 – 
 
c.
 
634delA resulting in p.R212fsX215
 
Patients II:1 and II:2 are siblings, diagnosed with primary adrenal
insufficiency at the ages of 1 and 16 months, respectively. Parents
were first cousins and patient II:1 presented at 10 days of age with
neonatal sepsis and severe hypoglycaemia. Biochemical investiga-
tions revealed an undetectable cortisol of < 30 nmol/l (N.R. 120–
620 nmol/l). At diagnosis plasma renin concentration was elevated
at 433 
 
μ
 
U/ml (N.R. 3·9–49·3 
 
μ
 
U/ml) while aldosterone was 470 pmol/l
(N.R. 100–440 pmol/l). Serum electrolytes were normal. Glucocorticoid
replacement therapy was initiated soon afterwards. Reassessment
while on treatment showed an elevation of renin levels of 68·7 
 
μ
 
U/ml,
while aldosterone was normal 190 pmol/l. At 4·8 years of age she
developed obstructive-hypertrophic cardiomyopathy necessitating
treatment with Verapamil. She continues to grow well, weight > 99th
centile and 75th centile for height. Her brother (patient II:2)
presented at 16 months of age with hypoglycaemic seizures.
Biochemical assays at diagnosis revealed an elevated ACTH level of
> 1250 pg/ml (N.R. < 50) and undetectable cortisol. As with his
sibling, his renin level was elevated to 63 
 
μ
 
U/ml (N.R. 3·3–41 
 
μ
 
U/ml),
with normal Aldosterone (320 pmol/l; N.R. 83–840). Renin levels
remained high despite relatively high doses of hydrocortisone
replacement. Plasma renin concentration was 80·20 
 
μ
 
U/ml and
aldosterone 650 pmol/l. He remains clinically well on treatment with
hydrocortisone 23 mg/m
 
2
 
/day. Mutation analysis of both affected
children revealed a novel homozygous 634delA mutation leading to
a frameshift at position 212 and an early stop codon at position 215
(p.R212fsX215). Parents were heterozygous for this variant.
 
Patient III:1 – 
 
c.
 
702delC resulting in p.F235fsX241
 
Patient III:1 presented at 7 weeks of age with hypoglycaemia,
hyperpigmentation, prolonged jaundice and failure to thrive. He is
of Sudanese origin and parents are first cousins. Plasma ACTH levels
at diagnosis were extremely elevated at > 1250 pg/ml (N.R. < 50 pg/ml)
paired with a serum cortisol of < 30 nmol/l. He was hypoglycaemic
(blood glucose < 1·1 mmol/l) at diagnosis and a short synacthen test
confirmed the diagnosis of adrenal insufficiency, with no cortisol
response to 1–24 ACTH. Serum electrolytes were reportedly normal
throughout childhood. PRA at age 1·0 years was 3·5 pmol/ml/h
(N.R. 1·3–8·6 pmol/ml/h). The corresponding plasma aldosterone
levels were low at 70 pmol/l (N.R. 300–2200), and on repeating
1 month later PRA was normal at 5·6 pmol/ml/h while aldosterone
remained slightly low at 290 pmol/l (N.R. 300–2200). The child is
thriving on treatment with height > 75th centile and weight > 99th
centile. Treatment continues at a hydrocortisone dose of 20 mg/m
 
2
 
/day.
Adrenal autoantibody screen was negative. Mutational analysis of the
MC2R revealed a homozygous deletion of a cytosine (C) nucleotide,
resulting in a frameshift at amino acid position 235 and premature
stop codon.
 
Patient IV:1 and IV:2 – 
 
c.
 
539C>A (p.S180X)
 
Patients IV:1 and IV:2, siblings of Lebanese origin, both presented
with hypoglycaemia and seizures in early childhood. At presentation
ACTH levels were high with undetectable cortisol levels. Both
children were persistently hyperpigmented with high ACTH levels
despite high hydrocortisone replacement dosages. They have had
repeated infections associated with seizures requiring numerous
episodes in hospital. Patient IV:2 had elevated PRA at diagnosis,
> 19 pmol/ml/h (N.R. 1·2–5·3 pmol/ml/h) with a corresponding
normal aldosterone level of 939 pmol/l (N.R. 83–941 pmol/l). At
follow-up, renin concentration was normal with a corresponding
aldosterone level in the low normal ranges (renin at 12·8 ng/l; N.R.
7·4–56·2 ng/l, and plasma aldosterone level 103 pmol/l (N.R. 83–
941 pmol/l). Patient IV:1 was noted to have normal to intermittently
elevated PRA on treatment (0·6–9·1 pmol/ml/h). Serum electrolytes
were normal. On sequencing the MC2R both children have a
homozygous nonsense mutation with a nucleotide substitution
(C > A) at nucleotide position 539. The result of this is the intro-
duction of a stop codon at position 180 (p.S180X). This would result
in a severely truncated protein at this position that lacks the 6th and
7th transmembrane domains, third intracellular loop, third
extracellular loop and the C terminal tail.
 
Discussion
 
The diagnosis of FGD is classically based upon the presence of
isolated glucocorticoid deficiency and the absence of mineralocorticoid
deficiency. Transient changes in sodium homeostasis are known to
occur at times of acute illness and can partly explain how patients
may be misdiagnosed with salt-losing adrenal hypoplasia.
 
8,10,11
 
ACTH is generally considered to play a less prominent role compared
to angiotensin II in the control of aldosterone production in the
human. However the Mc2r
 
–/–
 
 mouse suggests a more directly important
role. Mc2r
 
–/–
 
 mice were shown to have significantly lower, though
not undetectable, serum aldosterone levels compared to wild-type
litter mates. This is accompanied by increased adrenal AT1bR expression,
while CYP11B2 (aldosterone synthase) expression remains low.
Renin levels or activity were not measured.
 
12,13
 
 However these
findings contrast with recently published studies on Pomc
 
–/–
 
 mice
which demonstrate the presence of secondary hyperaldosteronism
in the complete absence of ACTH.
 
15
 
 The differences between these
two models are not entirely clear. The mechanism of hyper-
aldosteronism in the Pomc
 
–/–
 
 model is probably secondary to
the hypotensive effect of glucocorticoid deficiency which leads to
activation of the renin–angiotensin system. Why this effect is
not seen in the Mc2r
 
–/–
 
 animals is not clear, but might reflect a
developmental role for this receptor in the mouse.
The Mc2r
 
–/–
 
 mouse phenotype also appears to contrast with the
‘human equivalent’, that is, FGD patients with MC2R mutations.
These patients have normal mineralocorticoid status. One
explanation is that the majority of MC2R mutations are missense
mutations with some retention of function, and hence do not
 Mineralocorticoid deficiency in FGD
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represent a human equivalent of an MC2R knockout.
 
1–5,7,8
 
 Instead,
homozygous nonsense/frameshift mutations may represent a more
appropriate group to compare with Mc2r
 
–/–
 
 mice, although such
patients are extremely uncommon. The six patients described in this
article represent a unique cohort found to have homozygous
frameshift and nonsense mutations of the MC2R (Fig. 1). All six
children presented in either the neonatal period or in infancy.
Presenting symptoms were typical and include hypoglycaemia,
hyperpigmentation, neonatal hepatitis, prolonged jaundice, seizures
and failure to thrive. All six had very low or undetectable serum
cortisol paired with extremely elevated plasma ACTH levels.
This series demonstrates that some patients with severe MC2R
mutations have some degree of disturbance of the renin–angiotensin–
aldosterone axis, although no patient was frankly mineralocorticoid
deficient or required treatment with 9
 
α
 
-fludrocortisone. Of the six
patients described, elevated renin levels or PRA on follow-up were
noted in three. The corresponding aldosterone level was low on one
occasion on follow-up in one (patient I:1) and slightly low on
follow-up in patient III:1 in association with normal renin levels.
All patients were well during reassessment. None of the six patients
have received treatment with 9
 
α
 
-fludrocortisone. Hydrocortisone
has some mineralocorticoid activity and this may be sufficient may
blunt evidence of aldosterone deficiency in replaced patients.
Thus while it remains possible that some patients with nonsense muta-
tions may have been diagnosed with either primary adrenal hypoplasia
or early onset antibody negative Addison’s disease, it seems unlikely
that a distinct phenotype resulting from this type of mutation exists.
In conclusion, we believe it is unlikely that a distinct group of patients
with inherited failure of adrenal glucocorticoid and mineralocorticoid
production results from MC2R defects, and that the classical FGD
phenotype with isolated glucocorticoid deficiency is the typical clinical
consequence of any inactivating mutation of this receptor.
 
Acknowledgements
 
Authors are grateful to Professor J. Burrin and Dr L. Perry for their
advice on renin and aldosterone assays. LFC is a MRC Clinical Research
Training Fellow and LAM is supported by the Wellcome Trust.
 
References
 
1 Metherell, L.A., Chan, L.F. & Clark, A.J. (2006) The genetics of ACTH
resistance syndromes. 
 
Best Practice and Research Clinical Endocrinology
and Metabolism
 
, 
 
20
 
, 547–560.
2 Clark, A.J., McLoughlin, L. & Grossman, A. (1993) Familial Gluco-
corticoid Deficiency associated with point mutation in the
adrenocorticotropin receptor. 
 
Lancet
 
, 
 
341
 
, 461–462.
3 Tsigos, C., Arai, K., Hung, W. 
 
et al.
 
 (1993) Hereditary isolated
glucocorticoid deficiency is associated with abnormalities of the
adrenocorticotropin receptor gene. 
 
Journal of Clinical Investigation
 
,
 
92
 
, 2458–2461.
4 Elias, L.L., Huebner, A., Pullinger, G.D. 
 
et al.
 
 (1999) Functional
characterization of naturally occurring mutations of the human
adrenocorticotropin receptor: poor correlation of phenotype and
genotype. 
 
Journal of Clinical Endocrinology and Metabolism
 
, 
 
84
 
,
2766–2770.
5 Fluck, C.E., Martens, J.W., Conte, F.A. 
 
et al.
 
 (2002) Clinical, genetic,
and functional characterization of adrenocorticotropin receptor
mutations using a novel receptor assay. 
 
Journal of Clinical Endo-
crinology and Metabolism
 
, 
 
87
 
, 4318–4323.
6 Naville, D., Barjhoux, L., Jaillard, C. 
 
et al.
 
 (1996) Demonstration by
transfection studies that mutations in the adrenocorticotropin receptor
gene are one cause of the hereditary syndrome of glucocorticoid
deficiency. 
 
Journal of Clinical Endocrinology and Metabolism
 
, 
 
81
 
,
1442–1448.
7 Chung, T.T., Webb, T.R., Chan, L.F. 
 
et al.
 
 (2008) The majority of
ACTH receptor mutations found in Familial Glucocorticoid
Deficiency type 1 lead to defective trafficking of the receptor to the
cell surface. 
 
Journal of Clinical Endocrinology and Metabolism
 
, 
 
93
 
,
4948–4954.
8 Lin, L., Hindmarsh, P.C., Metherell, L.A. 
 
et al.
 
 (2007) Severe loss-
of-function mutations in the adrenocorticotropin receptor (ACTHR,
MC2R) can be found in patients diagnosed with salt-losing adrenal
hypoplasia. 
 
Clinical Endocrinology
 
, 
 
66
 
, 205–210.
9 Tsigos, C., Arai, K., Latronico, A.C. 
 
et al.
 
 (1995) A novel mutation
of the adrenocorticotropin receptor (ACTH-R) gene in a family
with the syndrome of isolated glucocorticoid deficiency, but no
ACTH-R abnormalities in two families with the triple A syndrome.
 
Journal of Clinical Endocrinology and Metabolism
 
, 
 
80
 
, 2186–
2189.
10 Clark, A.J. & Weber, A. (1998) Adrenocorticotropin insensitivity
syndromes. 
 
Endocrine Review
 
, 
 
19
 
, 828–843.
11 Davidai, G., Kahana, L. & Hochberg, Z. (1984) Glomerulosa failure
in congenital adrenocortical unresponsiveness to ACTH. 
 
Clinical
Endocrinology
 
, 
 
20
 
, 515–520.
12 Chida, D., Nakagawa, S., Nagai, S. 
 
et al.
 
 (2007) Melanocortin 2
receptor is required for adrenal gland development, steroidogenesis,
and neonatal gluconeogenesis. 
 
Proceedings of the National Academy
of Sciences USA
 
, 
 
104
 
, 18205–18210.
13 Chida, D., Sato, T., Sato, Y. 
 
et al.
 
 (2009) Characterization of mice
deficient in Melanocortin 2 receptor on a B6/Balbc mix background.
 
Molecular and Cellular Endocrinology
 
, 
 
300
 
, 32–36.
14 den Dunnen, J.T. & Antonarakis, S.E. (2000) Mutation nomenclature
extensions and suggestions to describe complex mutations: a dis-
cussion. 
 
Human Mutation
 
, 
 
15
 
, 7–12.
15 Linhart, K.B. & Majzoub, J.A. (2008) Pomc knockout mice have
secondary hyperaldosteronism despite an absence of adrenocortico-
tropin. 
 
Endocrinology
 
, 
 
149
 
, 681–686.
Fig. 1 Schematic representation of the MC2R, showing the position of the 
nonsense and frameshift mutations identified in six patients described in this 
study (filled circles).
